Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06403436
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-04-12
Brief Title:
A Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Sponsor:
TOLREMO therapeutics AG
Organization:
TOLREMO therapeutics AG
Study Overview
Official Title:
A Phase 1 First-in-Human Open-label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TT-CSP-001
Brief Summary:
The purpose of this study is to test the safety and therapeutic effect of TT125-802 single agent in subjects with advanced solid tumors
Detailed Description:
The purpose of this Phase 1 First-in-Human Open-label Study is to assess the safety tolerability pharmacokinetics pharmacodynamics and efficacy of TT125-802 as single agent in subjects with advanced solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None